Plasma Fractions Platform
The global fraction market represents $6 billion in revenues and encompasses a broad range of innovative therapies for the treatment of a variety of acute and chronic diseases. Following decades of robust growth and superior profitability, (in the 1990's) the blood products industry was beset by a series of challenges which threatened global supply and destabilized the majority of market participants. Such challenges included: contamination, collection shortages, heightened regulatory scrutiny, widespread manufacturing shut-downs, unstable production, collapsed pricing, clinical shortfalls, poor quality standards, technologic deficiencies, high fixed costs, and, rising capital expenditures. Plasma Fractions - as a therapeutic class - remain among the safest and most efficacious treatments for a variety of chronic and acute indications. In fact, due to (i) their robust clinical characteristics, (ii) their ability to be universally administered, (iii) their widespread availability due to the ability to be manufactured at global scales, plasma fractions are the most ideal means of treating and protecting whole populations who might become afflicted with a series of infectious and pathogen-related diseases. Healthios developed its plasma fractions platform through designing and implementing a comprehensive strategic, organization, and financial framework for the recovery of the plasma fractions market, elements of which included: the recruitment of a series of management teams; the development of detailed financial models; the design of complex capacity utilization scenarios to predict volume levels associated with plasma collection, fractionation, purification, fill/finish, and distribution on an industry-wide basis. Healthios also collaborated with top-tier institutional investors to sponsor the re-capitalization of select industry competitors and engaged with principal market competitors to develop far-reaching partnership opportunities.